New protocols, remote patient monitoring, and improved standards of care among ways industry can take next steps in CAR T-cell research.
Jaydev Thakkar, MBA
Advertisement
Jaydev Thakkar, MBA, MCA, is Chief Operating Officer of Biofourmis
Articles by Jaydev Thakkar, MBA
Advertisement
Latest Updated Articles
How Today’s Digitally Driven Research Could Drive CAR T-cell Therapy Protocols of the FuturePublished: September 25th 2023 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
2
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
3
Rethinking Operational Models to Reduce Site Burden in 2026
4
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
5